Candidate Targets of Dan-Lou Tablets in Hyperlipidemia-Associated Coronary Heart Disease
Chinese medicine and natural products · 01.06.2026 · 06 (02) · e125-e134
DOI: 10.1055/a-2886-0839 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chinese medicine and natural products, erschienen am 01.06.2026. Verfasst von Xiaofei Sun und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Objective
Coronary heart disease (CHD) is closely associated with dyslipidemia-driven atherosclerosis, in which macrophage-mediated inflammation links lipid deposition to plaque progression. Dan-Lou tablets (DLT), a traditional Chinese medicine preparation used clinically for CHD, have been reported to affect lipid and inflammatory pathways. This study aimed to identify candidate targets and pathways of blood-absorbed DLT constituents in hyperlipidemia-associated CHD and macrophage-associated inflammatory contexts.
Methods
Six blood-absorbed constituents of DLT (puerarin, formononetin, calycosin, paeoniflorin, tanshinone IIA, and cryptotanshinone) were investigated using an integrated network pharmacology and public transcriptomic strategy. Compound-related targets from TCMSP were intersected with hyperlipidemia-related genes from GeneCards, followed by enrichment analysis, protein-protein interaction analysis, macrophage-infiltration correlation analysis, GeneMANIA network analysis, and validation using the Gene Expression Omnibus dataset GSE179789.
Results
A total of 117 compound targets and 3,449 hyperlipidemia-related genes yielded 79 intersecting genes. Enrichment analysis highlighted lipid and atherosclerosis, interleukin signaling, fluid shear stress and atherosclerosis, AGE-RAGE signaling, hormone-related responses, and JAK-STAT-related pathways. Twenty-two genes showed relatively strong associations with inferred macrophage infiltration in the exploratory TCGA-LIHC analysis. CAV1, PTGIS, KLF9, and BCL2 showed differential expression in peripheral blood mononuclear cells from CHD patients before and after DLT treatment in GSE179789.
Conclusion
DLT may influence hyperlipidemia-associated CHD through candidate targets linked to lipid metabolism and macrophage-associated inflammatory pathways. Because the present work is based mainly on in silico prediction and public-dataset validation, the findings should be regarded as hypothesis-generating and require further experimental validation, particularly direct assessment of macrophage phenotype and function.
Zitieren
APA
Sun, X., Lin, J., Liang, C., Liu, J., Jiang, M., Liu, F., & Dong, P. (2026). Candidate Targets of Dan-Lou Tablets in Hyperlipidemia-Associated Coronary Heart Disease. Chinese medicine and natural products, 06(02), e125-e134. https://doi.org/10.1055/a-2886-0839
Vancouver
Sun X, Lin J, Liang C, Liu J, Jiang M, Liu F, et al. Candidate Targets of Dan-Lou Tablets in Hyperlipidemia-Associated Coronary Heart Disease. Chinese medicine and natural products. 2026;06(02):e125-e134. doi:10.1055/a-2886-0839
BibTeX
@article{Sun2026,
author = {Sun, Xiaofei and Lin, Jing and Liang, Chen and Liu, Jingjing and Jiang, Meixiu and Liu, Fangfang and Dong, Pengzhi},
title = {Candidate Targets of Dan-Lou Tablets in Hyperlipidemia-Associated Coronary Heart Disease},
journal = {Chinese medicine and natural products},
year = {2026},
volume = {06},
number = {02},
pages = {e125--e134},
doi = {10.1055/a-2886-0839}
}
EUVIMED